YOU ARE INVITED TO
Inside MEAI
New Insights from the CMND-100 Psychedelic Clinical Trial
YOU ARE INVITED TO
New Insights from the CMND-100 Psychedelic Clinical Trial
June 10, 2026
,
12 PM ET
This session provides an inside look at the clinical experience of MEAI, including early observations from the CMND-100 trial and the ability to enroll patients efficiently.
SPEAKERS
Dr. Adi Zuloff-Shani is a biomedical research and development executive with over 20 years of strategic and operational leadership in the healthcare industry, and a deep understanding of therapeutics development in heavily regulated environments.
Anahita Bassir Nia, MD, is an addiction psychiatrist and Assistant Professor of Psychiatry at the Yale School of Medicine. Her research focuses on developing novel treatments for addiction and stress-related disorders, alongside investigating their underlying neurobiological mechanisms. Her work centers on cannabinoids and psychedelics. She leads clinical trials examining the therapeutic potential of psychedelics and other novel compounds for alcohol use disorder, depression, and PTSD, while conducting mechanistic studi
.png)
Jennifer Ellis is an Assistant Professor and licensed clinical psychologist at Johns Hopkins Medicine. Her research focuses on identifying new therapeutics for substance use disorders and optimizing substance use treatment for individuals who enter care with co-occurring conditions.
HOST
Shannon Smadella is an award-winning social entrepreneur and business strategist with deep experience across the psychedelic sector, including advocacy, policy, and organizational leadership. As Co-Executive Director of World Psychedelics Day, Director of the International Psychedelics Awareness Foundation, and former board member of MAPS Canada, she has contributed to hundreds of interviews with leaders in psychedelic research and policy, including as a speaker, moderator, host, and interviewer.
PARTNERSHIPS
GET INVOLVED
